Josep Tabernero

Summary

Publications

  1. doi request reprint Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Expert Rev Anticancer Ther 8:1223-36. 2008
  2. doi request reprint Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy
    César Serrano
    Medical Oncology Department, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Cancer J 16:226-34. 2010
  3. ncbi request reprint Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer
    Rodrigo Dienstmann
    Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Medical Oncology Department, Passeig Vall d Hebron 119 129, Barcelona, Spain
    Curr Opin Investig Drugs 11:1434-41. 2010
  4. ncbi request reprint BRAF as a target for cancer therapy
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Anticancer Agents Med Chem 11:285-95. 2011
  5. doi request reprint Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
    Josep Tabernero
    Josep Tabernero, Rodrigo Dienstmann, Barbara Adamo, and Jordi Rodon, Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain Rastislav Bahleda, Anas Gazzah, and Jean Charles Soria, Gustave Roussy Cancer Campus and University Paris Sud, Villejuif Antoine Italiano, Institut Bergonie, Bordeaux, France Jeffrey R Infante, Sarah Cannon Research Institute, Nashville, TN Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA Bob Zhong, Suso J Platero, Moitreyee Chatterjee Kishore, Vijay Peddareddigari, and Feng R Luo, Janssen Research and Development, Raritan, NJ and Johan W Smit and Kim Stuyckens, Janssen Research and Development
    J Clin Oncol 33:3401-8. 2015
  6. doi request reprint Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
    Josep Tabernero
    Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain Electronic address
    Lancet Oncol 16:937-48. 2015
  7. doi request reprint Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain Electronic address
    Lancet Oncol 16:499-508. 2015
  8. pmc Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab
    Josep Tabernero
    Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119 129, Barcelona, 08035, Spain
    Target Oncol 10:65-76. 2015
  9. pmc Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain Division of Oncology, University of Washington, Seattle, Washington, USA Department of Oncology Hematology, Sarah Cannon Research Institute, Nashville, Tennessee, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Oncology, Peninsula Oncology Centre, Monash University, Frankston, Victoria, Australia Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA Division of Clinical Oncology, Medizinische Universität Wien, Vienna, Austria Mayo Clinic, Scottsdale, Arizona, USA Department of Oncology, Prince of Wales Hospital, Randwick, New South Wales, Sydney, Australia Celgene Corporation, Summit, New Jersey, USA Department of Oncology, Virginia G Piper Cancer Center at Scottsdale Healthcare TGen, Scottsdale, Arizona, USA
    Oncologist 20:143-50. 2015
  10. pmc Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
    Jeonghee Cho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Mol Cancer 13:141. 2014

Detail Information

Publications88

  1. doi request reprint Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Expert Rev Anticancer Ther 8:1223-36. 2008
    ..In this review, the authors examine the development of oxaliplatin as well as the main trials that have positioned oxaliplatin as a key drug in the treatment of CRC...
  2. doi request reprint Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy
    César Serrano
    Medical Oncology Department, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Cancer J 16:226-34. 2010
    ..This topic review will focus on the molecular basis and the mechanisms of action of epidermal growth factor receptor inhibitors, the clinical trials in this field and future trends of such compounds in CRC...
  3. ncbi request reprint Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer
    Rodrigo Dienstmann
    Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Medical Oncology Department, Passeig Vall d Hebron 119 129, Barcelona, Spain
    Curr Opin Investig Drugs 11:1434-41. 2010
    ..Success in the ongoing phase III clinical trials in patients with advanced NSCLC would lead to necitumumab becoming a valuable addition to future therapeutic strategies in oncology...
  4. ncbi request reprint BRAF as a target for cancer therapy
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Anticancer Agents Med Chem 11:285-95. 2011
    ....
  5. doi request reprint Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
    Josep Tabernero
    Josep Tabernero, Rodrigo Dienstmann, Barbara Adamo, and Jordi Rodon, Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain Rastislav Bahleda, Anas Gazzah, and Jean Charles Soria, Gustave Roussy Cancer Campus and University Paris Sud, Villejuif Antoine Italiano, Institut Bergonie, Bordeaux, France Jeffrey R Infante, Sarah Cannon Research Institute, Nashville, TN Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA Bob Zhong, Suso J Platero, Moitreyee Chatterjee Kishore, Vijay Peddareddigari, and Feng R Luo, Janssen Research and Development, Raritan, NJ and Johan W Smit and Kim Stuyckens, Janssen Research and Development
    J Clin Oncol 33:3401-8. 2015
    ..This first-in-human study evaluates the safety, pharmacokinetics, and pharmacodynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493...
  6. doi request reprint Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
    Josep Tabernero
    Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain Electronic address
    Lancet Oncol 16:937-48. 2015
    ..This retrospective exploratory analysis investigated the clinical activity of regorafenib in biomarker subgroups of the CORRECT study population defined by tumour mutational status or plasma protein levels...
  7. doi request reprint Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain Electronic address
    Lancet Oncol 16:499-508. 2015
    ....
  8. pmc Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab
    Josep Tabernero
    Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119 129, Barcelona, 08035, Spain
    Target Oncol 10:65-76. 2015
    ..The successful future application of this combination of antitumor mechanisms may rely on the identification of predictive biomarkers. ..
  9. pmc Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain Division of Oncology, University of Washington, Seattle, Washington, USA Department of Oncology Hematology, Sarah Cannon Research Institute, Nashville, Tennessee, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Oncology, Peninsula Oncology Centre, Monash University, Frankston, Victoria, Australia Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA Division of Clinical Oncology, Medizinische Universität Wien, Vienna, Austria Mayo Clinic, Scottsdale, Arizona, USA Department of Oncology, Prince of Wales Hospital, Randwick, New South Wales, Sydney, Australia Celgene Corporation, Summit, New Jersey, USA Department of Oncology, Virginia G Piper Cancer Center at Scottsdale Healthcare TGen, Scottsdale, Arizona, USA
    Oncologist 20:143-50. 2015
    ..This analysis sought to further explore the relationship between clinical characteristics and survival in the MPACT trial and to identify potential predictors of overall survival and progression-free survival in patients with MPC...
  10. pmc Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
    Jeonghee Cho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Mol Cancer 13:141. 2014
    ..However, detailed mechanisms and genomic predictors for pharmacological response to these antibodies in colon cancer remain unclear...
  11. doi request reprint A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases
    Josep Tabernero
    Authors Affiliations Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology VHIO, Universitat Autònoma de Barcelona CRC Hospital Quirón de Barcelona, Barcelona, Spain AVEO Oncology, Cambridge, Massachusetts and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 20:2793-804. 2014
    ....
  12. pmc Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs
    Ben Markman
    Centre for Cancer Research, Monash Institute of Medical Research, Southern Health, Melbourne, Victoria, Australia
    Oncotarget 1:530-43. 2010
    ..It is hoped that these agents will circumvent some of the shortcomings of the rapalogs and lead to meaningful benefits for cancer patients...
  13. doi request reprint Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial
    Josep Tabernero
    Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Barcelona, Spain Electronic address
    Eur J Cancer 50:320-31. 2014
    ..In the present analysis, outcomes were evaluated in prespecified subgroups to assess the consistency of the treatment effect...
  14. doi request reprint Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial
    Josep Tabernero
    Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 19:2541-50. 2013
    ..This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)...
  15. doi request reprint First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Cancer Discov 3:406-17. 2013
    ..In addition, we show that biweekly intravenous administration of ALN-VSP was safe and well tolerated. These data provide proof-of-concept for RNAi therapeutics in humans and form the basis for further development in cancer...
  16. doi request reprint A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors
    Josep Tabernero
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6313-21. 2011
    ..This study evaluated the safety and tolerability of serdemetan, determined the pharmacokinetic and pharmacodynamic profiles, and identified a recommended phase II dose...
  17. ncbi request reprint Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 25:5225-32. 2007
    ....
  18. doi request reprint Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 11:2062-71. 2012
    ..2%). These results suggest that matching chemorefractory patients with colorectal cancer with targeted agents in phase I trials based on the current molecular profile does not confer a significant clinical benefit...
  19. doi request reprint Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Treat Rev 35:354-63. 2009
    ..In this review, the authors examine the development of monoclonal antibodies against EGFR and the effects of this blockage in cell cycle, as well as the most important trials with these monoclonal antibodies in several tumor types...
  20. doi request reprint Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    Albert Font
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Crta Canyet s n, 08916, Badalona, Barcelona, Spain
    Cancer Chemother Pharmacol 62:1075-83. 2008
    ....
  21. doi request reprint Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment
    Higinio Dopeso
    Group of Molecular Oncology, Molecular Biology and Biochemistry Research Center, CIBBIM Nanomedicine, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2375-82. 2010
    ..However, only 20% to 30% of patients show an objective response to irinotecan, and there is great need for new molecular markers capable of identifying the subset of patients who are unlikely to respond...
  22. doi request reprint Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers
    Jaume Capdevila
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Curr Opin Oncol 21:374-80. 2009
    ..The increasing development of new targeted therapies in human cancer has also impacted in these rare gastrointestinal malignancies providing a wide range of possibilities in the design of future clinical trials...
  23. doi request reprint Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 28:1181-9. 2010
    ....
  24. doi request reprint Development of PI3K inhibitors: lessons learned from early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:143-53. 2013
    ..We also discuss key unresolved translational questions related to the clinical development of inhibitors of the PI3K/AKT/mTOR pathway and propose designs for biomarker-driven trials to address those issues...
  25. doi request reprint Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma
    Fernando Rivera
    Medical Oncology Department, H U Marqués de Valdecilla, Santander, Spain
    Cancer Chemother Pharmacol 67:75-82. 2011
    ..We performed a phase II trial to explore the efficacy and toxicity of induction irinotecan-cisplatin (IC) followed by concurrent irinotecan-cisplatin and radiotherapy (IC/RT) in this setting...
  26. doi request reprint Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer
    Teresa Macarulla
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Colorectal Cancer 7:300-8. 2008
    ..Also, preliminary data suggest that cetuximab can be administered in a more convenient 2-week schedule in combination with standard chemotherapy...
  27. doi request reprint Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Clin Cancer Res 16:4876-83. 2010
    ..Tumor biopsy samples were taken to investigate the effect of saracatinib on Src activity in tumors...
  28. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011
    ..This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose...
  29. doi request reprint Targeted therapies in thyroid cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035, Barcelona, Spain
    Target Oncol 4:275-85. 2009
    ..The development of new, targeted therapies and their encouraging initial results have opened a hopeful opportunity of treatment for these orphan therapy tumor patients...
  30. doi request reprint A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Ps Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Invest New Drugs 30:299-305. 2012
    ..A phase I study was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), establish a safety profile, and to evaluate pharmacokinetics and efficacy of the drug...
  31. doi request reprint Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors
    Beatriz Pardo
    Institut Català d Oncologia and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 14:1116-23. 2008
    ....
  32. doi request reprint Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy
    Celina García-García
    Department of Experimental Therapeutics Laboratory, Vall d Hebron Institute of Oncology, Pg Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 18:2603-12. 2012
    ..The hypothesis is that the suppression of this pathway results in sensitization to anti-HER2 agents. However, this combinatorial strategy has not been comprehensively tested in models of trastuzumab and lapatinib resistance...
  33. doi request reprint Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer
    Francisco Javier Ramos
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Colorectal Cancer 7:S52-7. 2008
    ..K-ras mutation analysis may now be considered a new standard of care in the selection of patients for EGFR-targeted therapy...
  34. ncbi request reprint Phase II study of trabectedin in pretreated patients with advanced colorectal cancer
    Luis Paz-Ares
    Medical Oncology Deparment, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Colorectal Cancer 6:522-8. 2007
    ..This open-label, nonrandomized, phase II study was aimed at evaluating the efficacy and toxicity of trabectedin over a 3-hour intravenous infusion every 3 weeks in patients with pretreated advanced colorectal cancer...
  35. doi request reprint The role of salvage treatment in advanced colorectal cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Crit Rev Oncol Hematol 71:53-61. 2009
    ..With the possibility of active salvage therapy, surgery rescue approaches should be taken in account during all the course of the patients' disease...
  36. pmc Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer
    Catia Moutinho
    Affiliations of authors Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain CM, AM C, FJC, ME Medical Oncology Service, Catalan Institute of Oncology, Health Sciences Research Institute of the Germans Trias i Pujol Foundation, Barcelona, Spain AM C, EM B, AA Department of Medical Oncology CS, RS and Clinical Informatics Unit VN P, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L Hospitalet de Llobregat, Barcelona, Spain Department of Pathology, Germans Trias i Pujol Foundation, Barcelona, Spain EM Department of Hematology and Oncology, Ospedale Niguarda Ca Granda, Milan, Italy AS B, AC, SS Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain EE, JT Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Barcelona, Spain ME Institució Catalana de Recerca i Estudis Avançats ICREA, Barcelona, Spain ME
    J Natl Cancer Inst 106:djt322. 2014
    ..A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause...
  37. doi request reprint Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase
    Arijit Chakravarty
    Millennium Pharmaceuticals Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 71:675-85. 2011
    ..Outcomes of pharmacodynamic assays from skin and tumor biopsies were concordant in several patients. Together, these new pharmacodynamic assays provide evidence for Aurora A inhibition by MLN8054 in patient skin and tumor tissues...
  38. pmc Brush border myosin Ia has tumor suppressor activity in the intestine
    Rocco Mazzolini
    Group of Molecular Oncology, and Group of Drug Delivery and Targeting, Centro de Investigaciones en Bioquímica y Biología Molecular Nanomedicine, Vall d Hebron University Hospital Research Institute, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain
    Proc Natl Acad Sci U S A 109:1530-5. 2012
    ..These results identify MYO1A as a unique tumor-suppressor gene in colorectal cancer and demonstrate that the loss of structural brush border proteins involved in cell polarity are important for tumor development...
  39. pmc Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncologist 16:1729-40. 2011
    ..Ultimately, the predictive value of a side effect of molecular targeted therapies requires validation in prospective trials...
  40. ncbi request reprint Aurora kinase family: a new target for anticancer drug
    Teresa Macarulla
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Recent Pat Anticancer Drug Discov 3:114-22. 2008
    ..This review focuses in recent progress in the role of AK in tumorogenesis and the development of new anticancer drug against AK proteins. This manuscript also includes some relevant patents as well...
  41. ncbi request reprint New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era
    Jaume Capdevila
    Vall d Hebron University Hospital, Medical Oncology Department, Barcelona, Spain
    Expert Rev Anticancer Ther 7:1027-41. 2007
    ..In this review, the authors examine the most important trials with monoclonal antibodies and tyrosine kinase inhibitors in the treatment of advanced colorectal cancer...
  42. ncbi request reprint EGFR and KRAS in colorectal cancer
    Ben Markman
    Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Vall d Hebron University Hospital, Barcelona, Spain
    Adv Clin Chem 51:71-119. 2010
    ....
  43. doi request reprint Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, corrected Barcelona, Spain
    J Clin Oncol 26:1603-10. 2008
    ..In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors...
  44. pmc MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
    Celina García-García
    Experimental Therapeutics Group, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Clin Cancer Res 21:5499-510. 2015
    ..Several clinical studies are being conducted to test the tolerability and clinical activity of dual MEK and PI3K pathway blockade in solid tumors...
  45. pmc RHOA inactivation enhances Wnt signalling and promotes colorectal cancer
    Paulo Rodrigues
    1 Group of Molecular Oncology, CIBBIM Nanomedicine, Vall d Hebron University Hospital, Research Institute VHIR, Universitat Autonoma de Barcelona, Passeig Vall d Hebron, 119 129, Barcelona 08035, Spain 2 CIBER de Bioingeniería, Biomateriales y Nanomedicina CIBER BBN, 28029 Barcelona, Spain
    Nat Commun 5:5458. 2014
    ..These results constitute a shift from the current paradigm and demonstrate that RHO GTPases can suppress tumour progression and metastasis. ..
  46. ncbi request reprint Monoclonal antibodies in solid tumours
    Ben Markman
    Medical Oncology Service, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    Curr Clin Pharmacol 5:160-5. 2010
    ..In this commentary we review those mAbs now in routine use for solid tumours, interesting aspects of their use and future directions...
  47. doi request reprint Sorafenib in metastatic thyroid cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Endocr Relat Cancer 19:209-16. 2012
    ..033). In this retrospective trial, sorafenib showed antitumor efficacy in all histological subtypes of thyroid cancer, warranting further development in this setting...
  48. doi request reprint A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells
    Isabel Puig
    Authors Affiliations Translational Program, Stem Cells and Cancer Laboratory Molecular Oncology Group Genomics Cancer Group and Translational Genomics Group, Vall d Hebron Institute of Oncology VHIO Parc de Recerca Biomèdica de Barcelona PRBB, Centre d Imatge Molecular CRC Corporació Sanitària Departments of Pathology, Medical Oncology, and HBP Surgery and Transplantation, Vall d Hebron University Hospital, Universidad Autónoma de Barcelona and General Surgery Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 19:6787-801. 2013
    ....
  49. ncbi request reprint Novel targets for anticancer treatment development in colorectal cancer
    Teresa Macarulla
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Colorectal Cancer 6:265-72. 2006
    ..In this article, we review the current developmental status of some of the most advanced targeted therapies in the treatment of CRC...
  50. ncbi request reprint The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents
    Josep Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Mol Cancer Res 5:203-20. 2007
    ..The potential of this novel approach to anticancer therapy will be elucidated by large, ongoing clinical trials...
  51. doi request reprint Molecular prescreening to select patient population in early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Spain
    Nat Rev Clin Oncol 9:359-66. 2012
    ....
  52. ncbi request reprint Application of monoclonal antibodies as cancer therapy in solid tumors
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr Clin Pharmacol 7:137-45. 2012
    ..Here we provide an overview of monoclonal antibodies approved for use in clinical oncology and those currently in clinical development...
  53. doi request reprint Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics
    Teresa Macarulla
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 9:2844-52. 2010
    ..Pharmacodynamic analyses in mitotic cells of both skin and tumor provided proof of mechanism for Aurora A kinase inhibition. A more potent, selective, second-generation Aurora A kinase inhibitor, MLN8237, is in clinical development...
  54. ncbi request reprint Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2
    Rodrigo Dienstmann
    Medical Oncology Service, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain
    Recent Pat Anticancer Drug Discov 6:210-36. 2011
    ..This review will focus primarily on an analysis of newly developed inhibitors of this pathway that have entered clinical trials, and recently registered patents in this field...
  55. doi request reprint Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
    Rodrigo Dienstmann
    Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Barcelona, Center affiliated to the RTICC ISCiii, Spain Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, Washington
    Cancer Discov 5:598-609. 2015
    ..MET gene amplification emerged in 1 patient during Sym004 treatment, and a partial response was seen in a patient with EGFR(S492R) mutation that is predictive of cetuximab resistance...
  56. doi request reprint Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
    Oriol Arqués
    Stem Cells and Cancer Laboratory, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Clin Cancer Res 22:644-56. 2016
    ..Here we investigate Wnt-mediated resistance in patients treated with PI3K or AKT inhibitors in clinical trials and evaluate the efficacy of a new Wnt/tankyrase inhibitor, NVP-TNKS656, to overcome such resistance...
  57. doi request reprint A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Cancer Discov 1:213-21. 2011
    ..In this article, we analyze the results of the 2 largest studies ever completed in patients with PNETs and discuss the challenges for future drug development in this setting...
  58. ncbi request reprint Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
    Federico Rojo
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 24:4309-16. 2006
    ..The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study...
  59. doi request reprint Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035, Barcelona, Spain
    Oncologist 13:113-9. 2008
    ....
  60. doi request reprint Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study
    Jordi Giralt
    Department of Radiation Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Radiother Oncol 89:263-9. 2008
    ....
  61. doi request reprint Biomarker-driven patient selection for early clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
    Curr Opin Oncol 25:305-12. 2013
    ..Technical and logistical obstacles that may hinder progress of this approach will be discussed, along with the ethical and financial concerns...
  62. doi request reprint Panitumumab: a summary of clinical development in colorectal cancer and future directions
    Guillem Argiles
    Medical Oncology Department, Valld Hebron University Hospital, P Valld Hebron, 119 129, 08035 Barcelona, Spain
    Future Oncol 8:373-89. 2012
    ..In this article we review 10 years of drug development, focusing on the clinical evidence for panitumumab's indication in metastatic colorectal cancer and future strategies of investigation...
  63. ncbi request reprint Novel targets in gastric and esophageal cancer
    Claudia María Valverde
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    Crit Rev Oncol Hematol 59:128-38. 2006
    ..The emerging data from the clinical development of these compounds has provided novel opportunities in the treatment of EC and GC that will probably translate into clinical benefit for patients with these common malignancies...
  64. doi request reprint Molecular predictors of response to chemotherapy in colorectal cancer
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Cancer J 17:114-26. 2011
    ..Determination of molecular predictive factors before selection of chemotherapy is rapidly approaching us to the paradigm of individualized treatment of CRC...
  65. doi request reprint Intrinsic cancer subtypes--next steps into personalized medicine
    Cristina Santos
    Department of Medical Oncology, Catalan Institute of Oncology ICO, L Hospitalet de Llobregat, Av Gran Vía 199 203, 08907, Barcelona, Spain
    Cell Oncol (Dordr) 38:3-16. 2015
    ..Likewise, we will review the potential applicability of these new classifications in the clinical routine...
  66. pmc Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
    Daniel D Von Hoff
    From the Translational Genomics Research Institute, Phoenix, and Virginia G Piper Cancer Center, Scottsdale both in Arizona D D V H, R K R Cancer Specialists, Fort Myers, FL T E Arena Oncology Associates, Lake Success F P A, and Roswell Park Cancer Institute, Buffalo W W M both in New York University of Washington, Seattle E G C Sarah Cannon Research Institute Tennessee Oncology, Nashville J Infante Princess Margaret Hospital, Toronto M M Atlanta Cancer Care T S and Georgia Cancer Specialists M N S both in Atlanta Blokhin Cancer Research Center, Moscow S A T Southern Health, East Bentleigh, VIC M H, Prince of Wales Hospital, Sydney D G, and Bionomics, Thebarton, SA J Iglesias all in Australia San Raffaele Scientific Institute, Milan M R Tom Baker Cancer Centre, Calgary, AB, Canada S D Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore D L University of Pittsburgh Medical Center, Pittsburgh N B Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona J T Centro Integral Oncológico Clara Campal, Madrid M H University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium E V C and Celgene, Summit, NJ X W, M F R
    N Engl J Med 369:1691-703. 2013
    ..We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer...
  67. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain corrected
    J Clin Oncol 23:2521-33. 2005
    ....
  68. doi request reprint Circulating tumour cells and cell-free DNA as tools for managing breast cancer
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:377-89. 2013
    ..In this Review, we discuss the current status of blood-born biomarkers as surrogates for tissue-based biomarkers, and their burgeoning impact on the management of patients with breast cancer. ..
  69. ncbi request reprint Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Endocr Relat Cancer 14:221-32. 2007
    ..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
  70. doi request reprint Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Mol Oncol 6:15-26. 2012
    ..Preliminary results of clinical trials evaluating these approaches will be discussed in this manuscript, with emphasis on TKIs in lung cancer and mAbs in advanced colorectal cancer...
  71. doi request reprint New trends in epidermal growth factor receptor-directed monoclonal antibodies
    Ben Markman
    Medical Oncology Department, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Immunotherapy 1:965-82. 2009
    ..This review will focus on the EGFR signaling network, monoclonal antibodies against EGFR and the pertinent clinical trials in this field of oncology using such agents...
  72. doi request reprint Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
    Guillem Argiles
    Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, P Vall d Hebron 119 129, 08035 Barcelona, Spain Electronic address
    Eur J Cancer 51:942-9. 2015
    ..This study investigated regorafenib plus modified FOLFOX (mFOLFOX6) as first-line treatment of metastatic CRC...
  73. doi request reprint Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
    Irene Braña
    Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119 129, 08035, Barcelona, Spain
    Target Oncol 10:111-23. 2015
    ..Carlumab could be safely administered at 10 or 15 mg/kg in combination with standard-of-care chemotherapy and was well-tolerated, although no long-term suppression of serum CCL2 or significant tumor responses were observed. ..
  74. doi request reprint What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
    Jaume Capdevila
    Medical Oncology Department, Hospital Vall d Hebron, Barcelona, Spain Electronic address
    Crit Rev Oncol Hematol 92:83-106. 2014
    ..Biomarkers that could predict response to nintedanib are also discussed. ..
  75. doi request reprint Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors
    Ferry A L M Eskens
    Authors Affiliations Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Barcelona, Spain Eisai Inc, Woodcliff Lake, New Jersey Eisai Inc, Tsukuba, Japan and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 19:6296-304. 2013
    ..To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule...
  76. doi request reprint Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors
    Rodrigo Dienstmann
    Authors Affiliations Molecular Therapeutics Research Unit, Medical Oncology Department and Experimental Therapeutics Group, Vall d Hebron University Hospital, Barcelona, Spain
    Mol Cancer Ther 13:1021-31. 2014
    ..Here, we provide a review of the literature, with the aim of differentiating the genomic contexts in which these various types of inhibitors may potentially have superior activity...
  77. doi request reprint Genomic medicine frontier in human solid tumors: prospects and challenges
    Rodrigo Dienstmann
    Vall d Hebron University Hospital, P Vall d Hebron 119 122, Barcelona, Spain 08035
    J Clin Oncol 31:1874-84. 2013
    ....
  78. doi request reprint β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
    Stephan P Tenbaum
    Vall d Hebrón Institut d Oncología VHIO, Stem Cell and Cancer Laboratory, Barcelona, Spain
    Nat Med 18:892-901. 2012
    ..We propose that this evaluation could be essential to the provision of a safer and more effective personalized treatment...
  79. ncbi request reprint New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era
    Jaume Capdevila
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Discov Med 9:153-62. 2010
    ..Moreover, the encouraging initial results of first clinical trials have accelerated the development of placebo-controlled phase III studies that will assess the role of these new agents in the management of differentiated thyroid cancer...
  80. doi request reprint Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068
    Yibing Yan
    Authors Affiliations Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc, DNA Way, South San Francisco, California Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d Hebron Institute of Oncology, Barcelona Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 19:6976-86. 2013
    ..Therefore, we conducted pharmacodynamic studies with GDC-0068, an ATP competitive, selective Akt1/2/3 inhibitor, in preclinical models and in patients treated with this compound...
  81. ncbi request reprint Current issues in adjuvant treatment of stage II colon cancer
    Thierry Andre
    Service d Oncologie Medicale, Hopital Tenon, 4 rue de la Chine, 75970, Paris Cedex 20, France, and Vall d Hebron University Hospital, Barcelona, Spain
    Ann Surg Oncol 13:887-98. 2006
    ..In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial...
  82. doi request reprint Development of molecular biomarkers in individualized treatment of colorectal cancer
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Colorectal Cancer 10:279-89. 2011
    ..Personalized cancer medicine in the mCRC scenario seems to be near reality, but validation of many biomarkers in prospective clinical trials is urgently warranted...
  83. ncbi request reprint Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer
    Teresa Macarulla
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Onkologie 29:99-105. 2006
    ..In this review we describe the current status of therapeutic strategies based on EGFR inhibitors in the treatment of GI cancer...
  84. ncbi request reprint [Value of inhibition of signal transduction and epigenetic therapy concepts in cancer therapy]
    Josep Tabernero
    Vall d Hebron University Hospital, Medical Oncology Service, Barcelona, Spain
    Onkologie 28:43-7. 2005
  85. ncbi request reprint Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature
    Josep Tabernero
    Medical Oncology Service, Hospital de Sant Pau, Barcelona, Spain
    J Urol 171:164-7. 2004
    ..To evaluate the real incidence of a second GCTT in a southern European population the medical records of 623 patients with GCTT successfully treated between 1976 and 1993 at 2 university hospitals were reviewed...
  86. pmc Molecular dissection of microsatellite instable colorectal cancer
    Eduardo Vilar
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Discov 3:502-11. 2013
    ..New high-throughput genomic data have validated it, thus stressing the fact that it is ready to be applied clinically...
  87. doi request reprint Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence
    Pier Davide Angelini
    Preclinical Research, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Cancer Res 73:450-8. 2013
    ..Underscoring the functional relevance of the p95HER2-induced senescence secretome, we show that p95HER2-induced senescent cells promote metastasis in vivo in a non-cell-autonomous manner...
  88. pmc Micromanaging the classification of colon cancer: the role of the microRNAome
    Eduardo Vilar
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Clin Cancer Res 17:7207-9. 2011
    ..The mucosa-adenoma-carcinoma model can now integrate miRNAs into the known genetic alterations that drive the progression of colorectal neoplasia...